Using an app for motivational interviewing and AI to manage diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to improve diabetes management for individuals with Type 2 Diabetes Mellitus (T2DM) by combining app-based motivational interviewing with AI-powered personalized nudges delivered through a mobile application called Empower+. The study will evaluate the effectiveness of this approach through a randomized controlled trial (RCT) with three arms, focusing on the primary outcome of HbA1c levels at week 36. Secondary outcomes will assess cost-effectiveness, quality of life, medication adherence, diet, and physical activity. Participants will be required to use a smartwatch tracker and the Empower+ app to monitor their progress.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 21 years and above
* Have been diagnosed with diabetes (T2DM)
* Had HbA1c result of ≥ 7.5% within past 3 months
* Physically able to exercise
* Able to read and converse in English
* Able to download the Empower+ app, use the smartphone wearable tracker, and conform to the minimum smartwatch and app monitoring schedule

Exclusion Criteria:

* On bolus insulin treatment
* Require assistance with basic activities of daily living (BADL)
* Have planned major operation or surgical procedure within 9 months from the time of recruitment
* Cognitively impaired (scored \< 6 on the Abbreviated Mental Test)
* Currently pregnant or lactating
* Current participants of ongoing clinical trials involving the usage of a smartphone wearable tracker or mobile health app to assist diabetes management
* Past Empower study participants who refused to participate in future Empower studies

Where it's running

• SingHealth Polyclinic (Punggol)
  Singapore, Singapore Recruiting
• SingHealth Polyclinic (Sengkang)
  Singapore, Singapore Recruiting
• SingHealth Polyclinic (Tampines)
  Singapore, Singapore Recruiting

Study contacts

• Principal investigator: Lian Leng Low — Singhealth Foundation
• Study coordinator: Lian Leng Low
• Email: low.lian.leng@singhealth.com.sg
• Phone: 63265872

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Proliverenol for liver fat and insulin resistance in type 2 diabetes

  This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.

  Recruiting Phase 2 Universitas Sriwijaya · Palembang, South Sumatera · NCT07928661

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes

  This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.

  Recruiting Phase 1 Novo Nordisk A/S · Neuss · NCT07896109

• RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes

  This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.

  Recruiting Bionime Corporation · Ulm, Baden-Wurttemberg · NCT07889388

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin

  This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).

  Recruiting at 8 sites Phase 3 Amgen · San Diego, California and 7 other locations · NCT07866066

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.